InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,064.20
(
0.91%
)
US TECH 100
17,076.00
(
0.00%
)
Dow Jones
38,225.66
(
0.85%
)
Brent Oil
83.98
(
0.42%
)
Bitcoin
59,394.85
(
0.46%
)
Post# of 251692
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 827
Posts 119554
Boards Moderated 15
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 241123

Monday, 01/24/2022 3:20:22 PM

Monday, January 24, 2022 3:20:22 PM

Post# of 251692
PRDS—Ritonavir-related excerpt from S-1 filing (for registration of insider shares):

https://www.sec.gov/ix?doc=/Archives/edgar/data/0001822711/000119312522014843/d299901ds1.htm

In August 2021, we initiated our first-in-human trial for PBI-0451. This trial is anticipated to enroll up to 180 healthy volunteers. The Phase 1 study is a placebo-controlled, blinded, randomized, dose escalation study of PBI-0451 in healthy volunteers designed to evaluate the safety, tolerability, and pharmacokinetics of PBI-0451 after single and multiple ascending doses.

This study will also evaluate the drug-drug interaction potential of PBI-0451, including upon its coadministration with ritonavir.

Emphasis added.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up